Impact of the COVID-19 pandemic on outcomes for patients with lung cancer receiving curative-intent radiotherapy in the UK
Authors
Fornacon-Wood, IBanfill, Kathryn
Ahmad, S
Britten, A
Carson, C
Dorey, N
Hatton, M
Hiley, C
Jayaprakash, KT
Jegannathen, A
Kidd, AC
Koh, P
Panakis, N
Peedell, C
Peters, A
Pope, A
Powell, C
Stilwell, C
Thomas, B
Toy, E
Wicks, Kate
Wood, V
Yahya, S
Price, Gareth
Faivre-Finn, Corinne
Affiliation
The Christie NHS Foundation Trust, Manchester, UKIssue Date
2023
Metadata
Show full item recordAbstract
Aims: Previous work found that during the first wave of the COVID-19 pandemic, 34% of patients with lung cancer treated with curative-intent radiotherapy in the UK had a change to their centre's usual standard of care treatment (Banfill et al. Clin Oncol 2022;34:19-27). We present the impact of these changes on patient outcomes. Materials and methods: The COVID-RT Lung database was a prospective multicentre UK cohort study including patients with stage I-III lung cancer referred for and/or treated with radical radiotherapy between April and October 2020. Data were collected on patient demographics, radiotherapy and systemic treatments, toxicity, relapse and death. Multivariable Cox and logistic regression were used to assess the impact of having a change to radiotherapy on survival, distant relapse and grade ≥3 acute toxicity. The impact of omitting chemotherapy on survival and relapse was assessed using multivariable Cox regression. Results: Patient and follow-up forms were available for 1280 patients. Seven hundred and sixty-five (59.8%) patients were aged over 70 years and 603 (47.1%) were female. The median follow-up was 213 days (119, 376). Patients with stage I-II non-small cell lung cancer (NSCLC) who had a change to their radiotherapy had no significant increase in distant relapse (P = 0.859) or death (P = 0.884); however, they did have increased odds of grade ≥3 acute toxicity (P = 0.0348). Patients with stage III NSCLC who had a change to their radiotherapy had no significant increase in distant relapse (P = 0.216) or death (P = 0.789); however, they did have increased odds of grade ≥3 acute toxicity (P < 0.001). Patients with stage III NSCLC who had their chemotherapy omitted had no significant increase in distant relapse (P = 0.0827) or death (P = 0.0661). Conclusion: This study suggests that changes to radiotherapy and chemotherapy made in response to the COVID-19 pandemic did not significantly affect distant relapse or survival. Changes to radiotherapy, namely increased hypofractionation, led to increased odds of grade ≥3 acute toxicity. These results are important, as hypofractionated treatments can help to reduce hospital attendances in the context of potential future emergency situations.Citation
Fornacon-Wood I, Banfill K, Ahmad S, Britten A, Carson C, Dorey N, et al. Impact of the COVID-19 Pandemic on Outcomes for Patients with Lung Cancer Receiving Curative-intent Radiotherapy in the UK. CLINICAL ONCOLOGY. 2023 OCT;35(10):E593-E600. PubMed PMID: WOS:001080103900001. English.Journal
Clinical OncologyDOI
10.1016/j.clon.2023.07.005PubMed ID
37507280Additional Links
https://dx.doi.org/10.1016/j.clon.2023.07.005Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1016/j.clon.2023.07.005
Scopus Count
Collections
Related articles
- Changes in the Management of Patients having Radical Radiotherapy for Lung Cancer during the First Wave of the COVID-19 Pandemic in the UK.
- Authors: Banfill K, Croxford W, Fornacon-Wood I, Wicks K, Ahmad S, Britten A, Carson C, Dorey N, Hatton M, Hiley C, Thippu Jayaprakash K, Jegannathen A, Koh P, Panakis N, Peedell C, Pope A, Powell C, Stilwell C, Thomas B, Toy E, Wood V, Yahya S, Zhou SY, Price G, Faivre-Finn C
- Issue date: 2022 Jan
- Management of mediastinal relapse after treatment with stereotactic body radiotherapy or accelerated hypofractionated radiotherapy for stage I/II non-small-cell lung cancer.
- Authors: Kilburn JM, Lester SC, Lucas JT Jr, Soike MH, Blackstock AW, Kearns WT, Hinson WH, Miller AA, Petty WJ, Munley MT, Urbanic JJ
- Issue date: 2014 Apr
- Reduced Fractionation in Lung Cancer Patients Treated with Curative-intent Radiotherapy during the COVID-19 Pandemic.
- Authors: Faivre-Finn C, Fenwick JD, Franks KN, Harrow S, Hatton MQF, Hiley C, McAleese JJ, McDonald F, O'Hare J, Peedell C, Pope T, Powell C, Rulach R, Toy E
- Issue date: 2020 Aug
- Hypofractionated Image-guided Radiation Therapy (3Gy/fraction) in Patients Affected by Inoperable Advanced-stage Non-small Cell Lung Cancer After Long-term Follow-up.
- Authors: Agolli L, Valeriani M, Bracci S, Nicosia L, DE Sanctis V, Enrici RM, Osti MF
- Issue date: 2015 Oct
- Gemcitabine, cisplatin, and hyperfractionated accelerated radiotherapy for locally advanced non-small cell lung cancer.
- Authors: Zwitter M, Kovac V, Smrdel U, Strojan P
- Issue date: 2006 Sep